Neuralink's transition to mass production
Elon Musk announced Neuralink's transition to the phase of 'high-volume production' of brain chips in 2026. This move entails the implementation of an automated surgical procedure, making the implantation process significantly simpler. Human trials began in 2024 after receiving FDA approval. As of September 2026, 12 people in various countries have received Neuralink chips, which help compensate for the effects of paralysis.
The first patient to use the chip is already successfully controlling a cursor, playing video games, and posting on social media. In 2026, trials for a new implant called Blindsight, designed to restore vision to blind patients, will also begin. This development could significantly change the lives of people suffering from various neurological disorders.
Investments and technological development
In June 2026, Neuralink secured investments totaling 650 million dollars, indicating a growing interest in technologies that can change medical practices. Meanwhile, in 2026, SpaceX and Tesla are preparing to launch new projects, including the Starship V3 ship and the Cybercab autonomous taxi, respectively. This reflects the active development of technological infrastructure, in which Neuralink plays an important role.
The transition of Neuralink to mass production of brain chips and active investments indicate a growing interest in neurotechnology that can significantly improve the quality of life for people with neurological issues.
Successful trials and the introduction of new implants like Blindsight are expected to open new opportunities in medical practice and enhance treatment effectiveness. These events also reflect the overall trend in the technology sector, where companies are focusing on innovations capable of changing perceptions about medicine and technology as a whole.